Critical biomarkers guiding pan-cancer targeted therapy have emerged, emphasizing the importance of detecting multiple gene mutations in cancer patients for precise and effective treatment. The AmoyDx HANDLE Classic Panel encompasses 40 key solid tumor genes, enabling the detection of common mutations to support clinical therapeutic decisions with rapid turnaround time (TAT).